Illumina, Inc. Introduces VeraCode(R) ADME Core Panel for Pharmaceutical Research

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List. Leveraging Illumina’s innovative VeraCode technology, researchers using the product can analyze key ADME content in as little as one day, allowing studies to proceed faster and more efficiently than ever before.